When Your Vision Changes on Ozempic or Another GLP-1
For a lot of people, a GLP-1 medication has been the first thing that really worked. Blood sugar finally came down. The weight started to move. Ozempic, Wegovy, Mounjaro, Zepbound and the other drugs in this family are now some of the most prescribed medications in the country, and for good reason.
So it is understandable that when something odd happens with your eyesight, the medication is the last thing you think about. You blame a long day, a bad night of sleep, or needing new glasses. Most of the time, that may be right. But on November 9, 2026, the FDA announced that every GLP-1 medication must now carry a warning about a rare eye condition that can take away part of a person’s sight, sometimes overnight and sometimes for good. I want to explain what the FDA said, how to tell an ordinary blurry day from something that needs attention, and what Virginia law means for people who have already lost vision.
What the FDA Announced
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It happens when blood flow to the front of the optic nerve, the cable that carries what your eye sees to your brain, suddenly drops. Without enough blood flow, part of the nerve is damaged. The result is often painless vision loss in one eye, and in many cases that loss does not come back. The FDA now requires the makers of every drug in the GLP-1 class to add NAION to the Warnings and Precautions section of their labels. That includes semaglutide (Ozempic, Wegovy and Rybelsus), tirzepatide (Mounjaro and Zepbound), liraglutide (Victoza and Saxenda), dulaglutide (Trulicity), and the newer pill orforglipron (Foundayo), along with combination products such as Xultophy and Soliqua.
The agency based its decision on several kinds of evidence, including an analysis of 126 clinical trials. In those trials, NAION showed up at about 6.4 cases per 100,000 patient-years among people taking GLP-1 drugs, compared with about 3.8 among people who were not. That is still rare. And the FDA was careful to call it a potential increased risk. A warning is not a finding that the drug caused any one person’s vision loss. But it is a clear signal that patients and doctors should be watching for this, and it is a significant development for people who were never told to watch for it.
“My eyes feel fuzzy today.” When is it more than that?
This is the question I most want to answer, because I worry about two kinds of people. The first assumes every blurry morning is a crisis. The second brushes off something serious because it did not hurt and seemed like it might pass.
Plenty of things can make your vision blurry for a while. Big swings in blood sugar, which are common when someone first starts a diabetes medication, can do it. So can dry eyes, eye strain, allergies, and simply being tired. That kind of blur tends to affect both eyes, comes and goes, and clears up.
NAION tends to look different. Pay attention if you notice:
- A sudden change, often noticed on waking. Many people go to bed seeing normally and wake up with part of their vision gone or dimmed.
- One eye, not both. If you cover your good eye and the world looks darker, cloudier, or incomplete through the other one, that matters.
- A missing piece. A blind spot, a shadow, or a section of your view that seems blank. Many people describe losing the top or bottom half of what they see in one eye.
- Colors that look washed out or dimmer in one eye than the other.
- Blur that does not clear. Hours or days later, it is still there.
- No pain. This is what fools people. NAION usually does not hurt, so it is easy to wait it out.
Here is a simple check anyone can do: cover one eye, look at something familiar, then switch. If the two eyes do not see the same, call your eye doctor that day.
And please do not stop there. If you have been told you have NAION, an optic nerve stroke, a retinal stroke, or another sudden or severe loss of vision while taking one of these medications, that is worth a conversation with a qualified lawyer, too. Even if you are not sure what happened, or your doctor has not given it a name yet, we would rather hear from you than have you talk yourself out of calling.
What to Do First
Your health comes first. If you notice sudden vision changes, see an eye doctor right away. The FDA is telling doctors to send patients with suspected NAION to an ophthalmologist promptly. Do not stop or change your medication on your own. These drugs treat serious conditions. The FDA’s guidance is that patients who have had NAION should talk with their doctor about whether to continue, and that decision belongs to you and your doctor.
Why This Has Become a Legal Issue
Drug makers have a duty to warn about serious risks they know about or should know about. In prescription drug cases, the warning that often matters most is the one given to your doctor, because your doctor is the one deciding what to prescribe and what to watch for. When a risk is missing from the label, doctors cannot pass it along, and patients cannot watch for it. Questions about NAION and these drugs are not new. A 2024 study published in JAMA Ophthalmology reported an association between semaglutide and NAION, and lawsuits followed. In December 2025, federal vision loss cases against Novo Nordisk and Eli Lilly were brought together in a single multidistrict litigation in the Eastern District of Pennsylvania, separate from the earlier GLP-1 cases over stomach and digestive injuries. The FDA’s new warning does not decide those cases. But a central question in any drug injury case is what the manufacturer knew, and when it told patients and doctors. The new warning is part of that story. I am already working with Virginians who lost vision after taking these medications, and I expect more people will start connecting the dots now that the warning is public.
What Virginia Law Requires
If you have lost vision, timing matters. In Virginia, personal injury and product liability claims generally must be filed within two years under Virginia Code ยง 8.01-243. In most cases, that clock starts when the injury happens, not when you first learn that a medication may have played a role. With vision that changed months ago, or a diagnosis that took time to pin down, figuring out when the clock started is not always simple.
A claim against a drug manufacturer is different from a medical malpractice case. It is not about whether your doctor did something wrong; in most cases, your doctor did nothing wrong at all. It focuses on the drug, the warnings that came with it, and the medical evidence about your vision loss. The rules and limits that apply to malpractice claims in Virginia do not automatically apply here.
Every case turns on its own facts. Many people taking GLP-1 drugs also have diabetes, high blood pressure, or sleep apnea, which can raise the risk of NAION on their own. That does not mean you do not have a case. It means your records deserve a careful look from someone who knows what to look for. That is our job, not yours.
I don’t share any of this to alarm anyone. I share it so that a deadline doesn’t quietly make the decision for you.
Where to Begin
You do not need to have everything figured out before you reach out. If you can, start gathering:
- The name of your medication, and roughly when you started and stopped it. Your pharmacy label, receipts, or patient portal will usually show this.
- When you first noticed a change in your vision, and what it looked like.
- The names of the eye doctors or specialists you have seen, and any diagnosis they gave you.
- Notes on how the change has affected your daily life: driving, reading, work, or getting around.
Missing something? That’s okay. We can help you request records. And if you are not sure whether your medication was a brand-name drug or a compounded version, call anyway. We will help you find out.
If what you have read here sounds like your situation, I’m glad to talk it through with you. The consultation is free, and it commits you to nothing; it simply helps you understand where you stand. You can reach me at (434) 951-7200 or here.
This article is for general information only and is not legal or medical advice. Reading it does not create an attorney-client relationship. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Foundayo, Xultophy and Soliqua are trademarks of their respective owners. MichieHamlett is not affiliated with these companies.